Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Current Assets (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed Current Assets for 5 consecutive years, with $75.7 million as the latest value for Q4 2025.

  • For Q4 2025, Current Assets fell 44.92% year-over-year to $75.7 million; the TTM value through Dec 2025 reached $75.7 million, down 44.92%, while the annual FY2025 figure was $75.7 million, 44.92% down from the prior year.
  • Current Assets hit $75.7 million in Q4 2025 for Kezar Life Sciences, down from $94.5 million in the prior quarter.
  • Across five years, Current Assets topped out at $311.3 million in Q2 2022 and bottomed at $75.7 million in Q4 2025.
  • Average Current Assets over 5 years is $187.3 million, with a median of $176.6 million recorded in 2024.
  • Year-over-year, Current Assets skyrocketed 139.62% in 2022 and then crashed 44.92% in 2025.
  • Kezar Life Sciences' Current Assets stood at $211.7 million in 2021, then skyrocketed by 34.99% to $285.7 million in 2022, then decreased by 27.57% to $207.0 million in 2023, then crashed by 33.56% to $137.5 million in 2024, then plummeted by 44.92% to $75.7 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $75.7 million, $94.5 million, and $104.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.